Clinical Implications of Measuring Infliximab Levels and Human Anti-Chimeric Antibodies in Patients with Inflammatory Bowel Disease

被引：1

作者：

Rai, Tarun ^{[1
]}

Navaneethan, Udayakumar ^{[1
]}

Dalal, Deepan ^{[1
]}

Lashner, Bret ^{[1
]}

Shen, Bo ^{[1
]}

机构：

[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2012年 / 107卷

关键词：

D O I：

10.14309/00000434-201210001-01572

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1572

引用

页码：S634 / S634

页数：1

共 50 条

[31] Development of anti-infliximab antibodies increases infliximab clearance in chronic inflammatory bowel disease
Ternant, D.
Aubourg, A.
Magdelaine-Beuzelin, C.
Degenne, D.
Watier, H.
Picon, L.
Paintaud, G.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 23 - 23
[32] INDUCTION ANTI-TNF DRUG LEVELS AND ANTIBODIES AT WEEK 6 IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS TREATED WITH INFLIXIMAB
Garcia, Karoline S.
Queiroz, Natalia S.
Parra, Rogerio S.
Feres, Omar
Chebli, Julio
Chebli, Liliana A.
Flores, Cristina
Vieira, Andrea
Azevedo, Matheus
Carlos, Alexandre S.
Oba, Jane
Alves, Olivia D.
Ceara, Christianne D.
Sipahi, Aytan M.
Damiao, Aderson O.
GASTROENTEROLOGY, 2022, 162 (07) : S1097 - S1097
[33] Detection of Anti Infliximab Antibodies in Patients with Inflammatory Bowel Disease (IBD) in the Presence of Infliximab by Homogeneous Liquid Phase Anti Infliximab Mobility Shift Assay
Eser, Alexander
Primas, Christian
Shringarpure, Reshma
Hauenstein, Scott
Wang, Shui Long
Reinisch, Walter
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S657 - S657
[34] Clinical role, optimal timing and frequency of measurement of serum infliximab levels and anti-infliximab antibody titres in patients with inflammatory bowel disease
Bor, R.
Farkas, K.
Balint, A.
Milassin, A.
Rutka, M.
Matuz, M.
Nagy, F.
Fabian, A.
Szepes, Z.
Molnar, T.
JOURNAL OF CROHNS & COLITIS, 2016, 10 : S358 - S358
[35] Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit
Mihika B. Dave
Alpa J. Dherai
Devendra C. Desai
Bhamini G. Keny
Dhanashri N. Shetty
Satish Kulkarni
Kiran Peddy
Tester F. Ashavaid
Indian Journal of Gastroenterology, 2020, 39 : 426 - 434
[36] Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit
Dave, Mihika B.
Dherai, Alpa J.
Desai, Devendra C.
Keny, Bhamini G.
Shetty, Dhanashri N.
Kulkarni, Satish
Peddy, Kiran
Ashavaid, Tester F.
INDIAN JOURNAL OF GASTROENTEROLOGY, 2020, 39 (05) : 426 - 434
[37] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
Strik, A. S.
van den Brink, G. R.
Ponsioen, C.
Mathot, R.
Loewenberg, M.
D'Haens, G. R.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
[38] Clinical Utility of Measuring Infliximab (IFX) and Adalimumab (ADA) and Anti-drug Antibody Levels Using the LabCorp Assay in Patients With Inflammatory Bowel Disease (IBD)
Brown, Sara
Perinbasekar, Rajiv
Syed, Nauroz
Lonsako, Shumet
Cross, Raymond
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S406 - S406
[39] SERUM INFLIXIMAB LEVELS,ANTIBODIES TO INFLIXIMAB AND ALBUMIN CONCENTRATIONS DURING INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
Malickova, K.
Janatkova, I.
Duricova, D.
Bortlik, M.
Lukas, M.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 213 - 213
[40] Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice
Buurman, D. J.
Maurer, J. M.
Keizer, R. J.
Kosterink, J. G. W.
Dijkstra, G.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (05) : 529 - 539

← 1 2 3 4 5 →